menu
    • menu

    Company profile for Molecular Targeting Technologies

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    A clinical stage business, developing theranostics for rare cancers. A Centocor spinoff, we’re rooted in a decade of innovative collaborative research, a robust pipeline and an outstanding scientific network. In clinical development: EBTATE (177Lu-EBTATE) A long lived radiotherapeutic for gasteropancreatic neuroendocrine tumors (under license from the NIH) Early human testing showed EBTATE is safe and more effective than c...
    A clinical stage business, developing theranostics for rare cancers. A Centocor spinoff, we’re rooted in a decade of innovative collaborative research, a robust pipeline and an outstanding scientific network. In clinical development: EBTATE (177Lu-EBTATE) A long lived radiotherapeutic for gasteropancreatic neuroendocrine tumors (under license from the NIH) Early human testing showed EBTATE is safe and more effective than competitors. US trials begin in Q4 2020. EBRGD (177Lu-EBRGD) A long-lived radiotherapeutic for αvβ3 expressing tumors. We're targeting glioblastoma multiforme and non-small cell lung cancer. (under license from the NIH)

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Molecular Targeting TechnologiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    833 Lincoln Ave., Unit 9, West Chester, PA 19380
    Telephone
    Telephone
    610-738-7938
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mtarget.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/molecular-targeting-technologies-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Molecular Targeting Technologies Initiate Legal Action for EB-TRT
    Molecular Targeting Technologies Initiate Legal Action for EB-TRT

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014786176/en/Molecular-Targeting-Technologies-Inc.-Initiates-Legal-Action-Over-Unauthorized-Use-of-Albumin-binding-Evans-blue-Targeted-Radiotherapeutic-EB-TRT

    BUSINESSWIRE
    14 Oct 2025
    Share Share
    MTTI 225Ac-EBTATE Effective Against Neuroendocrine Tumors
    MTTI 225Ac-EBTATE Effective Against Neuroendocrine Tumors

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241209417234/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    MTTI Reports On Fast-Acting Tumor Visualization Molecule
    MTTI Reports On Fast-Acting Tumor Visualization Molecule

    12 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240912343730/en

    BUSINESSWIRE
    12 Sep 2024
    Share Share
    MTTI At 2nd Targeted Radionuclide Pharmaceuticals Summit
    MTTI At 2nd Targeted Radionuclide Pharmaceuticals Summit

    11 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240911755609/en

    BUSINESSWIRE
    11 Sep 2024
    Share Share
    MTTI Reports On 225Ac/177Lu-EBTATE Radiopharmaceuticals At SNMMI 2024
    MTTI Reports On 225Ac/177Lu-EBTATE Radiopharmaceuticals At SNMMI 2024

    21 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240521449624/en

    BUSINESSWIRE
    21 May 2024
    Share Share
    Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
    Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer

    02 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230802243597/en

    BUSINESSWIRE
    02 Aug 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search